Key Findings:  CBD is a very low-affinity agonist at CB1 that can nevertheless affect CB1 receptor activity in vivo in an indirect manner. THCV is a high-affinity antagonist at CB1 in vitro but only occasionally produces effects in vivo. THCV has also high affinity for CB2 receptors and signals as a partial agonist, differing from both CBD and rimonabant.
Type of Study:  Meta-analysis
Study Result:  Positive
Study Location(s):  Italy, United Kingdom
Year of Pub:  2015
Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source:  Unspecified
Receptors Studied:  CB1, CB2